Molecular Templates has developed a new class of targeted biologic therapies. Engineered Toxin Bodies (ETBs) are derived from bacterial toxins that have been engineered to have distinct target specificity and reduced immunogenicity while retaining the biologically active features and predictable pharmacokinetics of the parent toxin. ETBs possess unique biological properties that allow them to gain cell entry through targets that may not normally internalize, actively route themselves intracellularly, and enzymatically trigger apoptosis in the target cell. These features confer a host of advantages for target identification, lead discovery, and drug development over therapeutic antibody and small molecules approaches. Vast libraries of ETBs have been created that can be rapidly screened for specific and potent cell kill to identify promising therapeutics. Molecular Templates has created vast libraries of ETBs. Each ETB has a distinct binding affinity but retains the biologically active properties of the parent toxin. ETBs are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Molecular Templates is developing a number of lead ETB candidates against a variety of validated and novel cancer targets. These lead ETBs range from IND enabling to early preclinical characterization stages of development.